• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prolonged Survival and Preserved Renal Graft Function in a Kidney Transplant Patient With Advanced Urothelial Carcinoma Using an Immune Checkpoint Inhibitor: A Case Report.

作者信息

Mavichak Weerawaroon, Laowalert Suthanit, Ativitavas Touch, Rungprai Daraporn

机构信息

Blackpool Victoria Hospital, Blackpool, United Kingdom.

Kidney Transplant Institute, Department of Medicine, Praram 9 Hospital, Bangkok, Thailand.

出版信息

Transplant Direct. 2023 Jun 28;9(7):e1509. doi: 10.1097/TXD.0000000000001509. eCollection 2023 Jul.

DOI:10.1097/TXD.0000000000001509
PMID:37389014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10306423/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec16/10306423/ef82f1eb05a8/txd-9-e1509-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec16/10306423/e16e859e5d2c/txd-9-e1509-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec16/10306423/ef82f1eb05a8/txd-9-e1509-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec16/10306423/e16e859e5d2c/txd-9-e1509-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec16/10306423/ef82f1eb05a8/txd-9-e1509-g002.jpg

相似文献

1
Prolonged Survival and Preserved Renal Graft Function in a Kidney Transplant Patient With Advanced Urothelial Carcinoma Using an Immune Checkpoint Inhibitor: A Case Report.使用免疫检查点抑制剂治疗晚期尿路上皮癌的肾移植患者的长期生存及保留肾移植功能：一例报告
Transplant Direct. 2023 Jun 28;9(7):e1509. doi: 10.1097/TXD.0000000000001509. eCollection 2023 Jul.
2
Current status and future perspectives of immunotherapy against urothelial and kidney cancer.免疫治疗在膀胱癌和肾癌中的现状与展望。
Jpn J Clin Oncol. 2021 Oct 5;51(10):1481-1492. doi: 10.1093/jjco/hyab121.
3
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.晚期泌尿生殖系统恶性肿瘤患者接受免疫检查点抑制剂治疗的结局特征。
Urol Oncol. 2021 Jul;39(7):437.e1-437.e9. doi: 10.1016/j.urolonc.2021.01.006. Epub 2021 Jan 23.
4
Urothelial carcinoma of the graft kidney with molecular analyses: a rare case report.移植物肾尿路上皮癌的分子分析：罕见病例报告。
Diagn Pathol. 2021 Jun 14;16(1):53. doi: 10.1186/s13000-021-01109-z.
5
BK virus-associated urothelial carcinoma of a ureter graft in a renal transplant recipient: a case report.肾移植受者输尿管移植物中BK病毒相关的尿路上皮癌：一例报告
Transplant Proc. 2014;46(2):616-9. doi: 10.1016/j.transproceed.2013.09.037.
6
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.晚期尿路上皮癌的组织学亚型与 PD-1/PD-L1 阻断治疗反应：一项回顾性研究。
J Urol. 2020 Jul;204(1):63-70. doi: 10.1097/JU.0000000000000761. Epub 2020 Jan 23.
7
Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study.检查点抑制剂治疗晚期肾细胞癌或尿路上皮癌合并慢性肾脏病患者的疗效和安全性：一项回顾性队列研究
Cancers (Basel). 2021 Apr 1;13(7):1623. doi: 10.3390/cancers13071623.
8
Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review.单独使用PD-1抑制剂有效治疗孤立性肾盏尿路上皮癌：一例报告及文献综述
Front Oncol. 2022 May 10;12:866013. doi: 10.3389/fonc.2022.866013. eCollection 2022.
9
Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor.移植肾转移性尿路上皮癌对免疫检查点抑制剂完全缓解
Case Rep Urol. 2020 Dec 23;2020:8881841. doi: 10.1155/2020/8881841. eCollection 2020.
10
Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report.阿替利珠单抗治疗晚期复发性基底细胞癌和膀胱癌：病例报告。
J Med Case Rep. 2022 Oct 31;16(1):396. doi: 10.1186/s13256-022-03634-x.

本文引用的文献

1
De novo upper tract urothelial carcinoma after renal transplantation: a single-center experience in China.肾移植后新发上尿路尿路上皮癌：中国单中心经验。
BMC Urol. 2023 Feb 20;23(1):23. doi: 10.1186/s12894-023-01190-0.
2
Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.帕博利珠单抗在真实环境下晚期尿路上皮癌患者中的临床获益：一项疗效和安全性的单中心研究。
Curr Oncol. 2022 Feb 10;29(2):945-955. doi: 10.3390/curroncol29020080.
3
Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management.
免疫检查点抑制剂与肾脏毒性：诊断与管理进展
Kidney Med. 2021 Oct 8;3(6):1074-1081. doi: 10.1016/j.xkme.2021.08.008. eCollection 2021 Nov-Dec.
4
Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗的患者中慢性肾脏病的发病率及预测因素和估计肾小球滤过率下降情况
Am J Kidney Dis. 2022 Jan;79(1):134-137. doi: 10.1053/j.ajkd.2021.05.012. Epub 2021 Jun 24.
5
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.帕博利珠单抗单药或联合化疗对比化疗作为晚期尿路上皮癌一线治疗（KEYNOTE-361）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26.
6
Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor.移植肾转移性尿路上皮癌对免疫检查点抑制剂完全缓解
Case Rep Urol. 2020 Dec 23;2020:8881841. doi: 10.1155/2020/8881841. eCollection 2020.
7
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.免疫检查点抑制剂在肾移植癌症患者中的安全性和疗效的多中心研究。
Kidney Int. 2021 Jul;100(1):196-205. doi: 10.1016/j.kint.2020.12.015. Epub 2020 Dec 24.
8
De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan.台湾地区心、肾、肝移植后新发恶性肿瘤：一项全国性研究。
Exp Clin Transplant. 2020 Apr;18(2):224-233. doi: 10.6002/ect.2019.0210. Epub 2020 Mar 4.
9
Urologic malignancies in kidney transplantation.肾脏移植中的泌尿系统恶性肿瘤。
Am J Transplant. 2018 Jan;18(1):13-22. doi: 10.1111/ajt.14533. Epub 2017 Dec 1.
10
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.一线帕博利珠单抗治疗铂类药物治疗禁忌的局部晚期和不可切除或转移性尿路上皮癌患者（KEYNOTE-052）：一项多中心、单臂、2 期研究。
Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.